A Phase 3 interventional study of CP-690,550 and CP-690,550 in Ulcerative Colitis, sponsored by Pfizer. Completed at 252 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-17.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing tofacitinib in Colitis, Ulcerative — 3 open to participants now, 6 under way, 1 of them phase 3. tofacitinib · Colitis, Ulcerative.
Among the 14 studies testing tofacitinib in Colitis, Ulcerative, this one has the largest enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 2nd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →3 of the 14 studies testing tofacitinib in Colitis, Ulcerative are open now, in 1 country. Recruiting first, the newest first:
Asian Institute of Gastroenterology, India · Sites in India
Ages 18–65
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18+
Post Graduate Institute of Medical Education and Research, Chandigarh
Ages 18–65
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 2008; this study’s year is marked. 4 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 944 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 107 across the 14 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 7 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Colitis, Ulcerative by Pfizer: 3 open now, 7 under way, 2 of them phase 3. Of 32 finished, 26 (81%) have results posted.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one has the largest enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 6th registered.
Pfizer’s Colitis, Ulcerative studies by the year they started, since 2005.
3 of the studies testing tofacitinib in Colitis, Ulcerative that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT07297069Asian Institute of Gastroenterology, IndiaCombination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial | 2027-05-31 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies testing tofacitinib in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 42 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This study is an open label, long-term extension study for subjects with moderate to severe ulcerative colitis designed to evaluate long term therapy of CP-690,550.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
5 mg BID
Drug: CP-690,550
10 mg BID
Drug: CP-690,550
5 mg tablets, BID, for at least 12 months
10 mg tablets, BID, for at least 12 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.
Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs)
Serious infections were treated infections that required parenteral antimicrobial therapy or hospitalization for treatment or; met other criteria that required the infection to be classified as a serious adverse event (SAE). SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state.
Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Number of Participants With Laboratory Test Abnormalities
Laboratory abnormalities: Hemoglobin, hematocrit, RBC: \<0.8\* LLN; reticulocytes (absolute \[Abs\], %): \<0.5\* LLN, \>1.5\* ULN; MCV, MCH: \<0.9\* LLN, \>1.1\* ULN; platelets:\<0.5\* LLN, \>1.75\* ULN; WBC:\<0.6\* LLN,\>1.5\* ULN; lymphocytes (Abs, %), total neutrophils (Abs,%):\<0.8\* LLN, \>1.2\* ULN; Basophils (Abs,%),eosinophils(Abs, %),monocytes(Abs, %):\>1.2\* ULN; total bilirubin,direct bilirubin,indirect bilirubin:\>1.5\* ULN; AST,ALT,gamma GT, LDH,ALP: \>3.0\* ULN; total protein,albumin: \<0.8\* LLN,\>1.2\* ULN: BUN,creatinine: \>1.3\* ULN;uric acid:\>1.2\* ULN; cholesterol,triglycerides: \>1.3\* ULN; cholesterol (HDL: \<0.8\* LLN; LDL: \>1.2\* ULN); sodium: \<0.95\* LLN, \>1.05\* ULN; potassium, chloride, calcium, bicarbonate: \<0.9\* LLN, \>1.1\* ULN; glucose: \<0.6\* LLN; creatine kinase \>2.0\* ULN; urine specific gravity: \<1.003; urine pH: \<4.5; urine (glucose,protein,blood,nitrite,leukocyte,esterase): \>=1; Urine (RBC,WBC): \>=20; urine epithelial cells:\>=6; urine (casts,granular casts,hyaline casts): \>1; urine bacteria:\>20.
Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Number of Participants With Vital Sign Abnormalities
Vital sign abnormalities included greater than or equal to (\>=) 30 millimeter of mercury \[mmHg\] increase in systolic blood pressure (BP), \>=30 mmHg decrease in systolic BP, Systolic BP (less than \[\<\] 90 mmHg), \>=20 mmHg increase in diastolic BP, \>=20 mmHg decrease in diastolic BP, diastolic BP (\<50 mmHg), pulse rate (\<40 beats per minute \[BPM\]), pulse rate (greater than \[\>\] 120 BPM).
Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline
Physical examinations included weight, general appearance, head, ears, eyes, nose, mouth, throat, thyroid, skin (presence of rash), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs, peripheral edema), abdominal (palpation and auscultation), perianal, musculoskeletal, extremities, neurologic (mental status, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Clinically significant changes were judged by the investigator.
Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Number of Participants With Electrocardiogram (ECG) Abnormalities
ECG abnormalities criteria: maximum PR interval (\>=300 millisecond); maximum QRS complex (\>=200 millisecond); and maximum QT interval (\>=500 millisecond).
Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Incidence Rates for Adjudicated Cardiovascular, Malignancy, Opportunistic Infections and Thromboembolic Safety Events
Incidence rates for adjudicated cardiovascular (major adverse cardiovascular event \[MACE\]), malignancy (non-melanoma skin cancer \[NMSC\], malignancies excluding NMSC, opportunistic infections (OIs) (both herpes zoster and non herpes zoster OIs) and thromboembolic (venous thromboembolism) safety events were analyzed. This outcome measure was measured in participants with events per 100 participants-years (pt with events/100 pts-yrs).
Time frame: Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group)
Number of Participants in Remission at Months 2, 12, 24 and 36: Observed Cases
Remission in participants was defined as a total Mayo score of less than or equals to (\<=) 2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and physician global assessment (PGA), each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Time frame: Months 2, 12, 24 and 36
Number of Participants in Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
Remission in participants was defined as a total Mayo score of \<=2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Time frame: Months 2, 12, 24 and 36
Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Observed Cases
Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Time frame: Months 2, 12, 24 and 36
Number of Participants in Clinical Remission at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
Time frame: Months 2, 12, 24 and 36
Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Observed Cases
PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.
Time frame: Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84
Number of Participants in Partial Mayo Score (PMS) Remission at Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total PMS score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.
Time frame: Months 1, 4, 6, 9, 15, 18, 21, 27, 30, 33, 39, 42, 45, 48, 51, 54, 57, 60, 63, 66, 69, 72, 75, 78, 81 and 84
Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Observed Cases
Mucosal healing in participants was defined as Mayo endoscopic sub score of 0 or 1. The Mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicated higher disease severity.
Time frame: Months 2, 12, 24 and 36
Number of Participants Who Achieved Mucosal Healing at Months 2, 12, 24 and 36: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
Mucosal healing in participants was defined as mayo endoscopic sub score of 0 or 1. The mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicating higher disease severity.
Time frame: Months 2, 12, 24 and 36
Number of Participants With Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score >=170 at Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84: Non-responder Imputation- Last Observation Carried Forward (NRI-LOCF)
IBDQ was a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease-specific quality of life in participants with inflammatory bowel disease (IBD), including ulcerative colitis consisted of 32 items scored from 1 (worst response) to 7 (best response). For each domain, higher score indicates better quality of life (QOL). Total IBDQ score was the sum of each item score, and ranged from 32 to 224 with a higher score indicated better QOL.
Time frame: Months 2, 6, 12, 18, 24, 30, 36, 48, 60, 72 and 84
Participants enrolled in this Study A3921139: 1) who had completed or had early withdrawal due to treatment failure in Study A3921096 (NCT01458574) 2) or who were non-responders after completing induction studies A3921094 (NCT01465763) or A3921095 (NCT01458951). Eligible participants assigned to either Tofacitinib 5 mg BID or 10 mg BID depending if participant was in remission at baseline of A3921139. Remission=total Mayo score \<=2 with no individual sub score \>1, rectal bleeding sub score =0.
| Milestone | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Started | 175 | 769 |
| Completed | 91 | 104 |
| Not completed | 84 | 665 |
| Withdrew: Adverse event | 20 | 80 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 20 | 326 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Did not meet entrance criteria | 0 | 1 |
| Withdrew: Pregnancy | 2 | 10 |
| Withdrew: Protocol violation | 2 | 7 |
| Withdrew: Withdrawal by subject | 24 | 79 |
| Withdrew: Other | 14 | 156 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and all non-serious AEs.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Participants with AEs | 154 | 626 |
| Participants with SAEs | 39 | 147 |
Serious infections were treated infections that required parenteral antimicrobial therapy or hospitalization for treatment or; met other criteria that required the infection to be classified as a serious adverse event (SAE). SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group that were absent before treatment or that worsened relative to pretreatment state.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Number of Participants With Serious Infections as Treatment Emergent Adverse Events (TEAEs) | 8 | 31 |
Laboratory abnormalities: Hemoglobin, hematocrit, RBC: \<0.8\* LLN; reticulocytes (absolute \[Abs\], %): \<0.5\* LLN, \>1.5\* ULN; MCV, MCH: \<0.9\* LLN, \>1.1\* ULN; platelets:\<0.5\* LLN, \>1.75\* ULN; WBC:\<0.6\* LLN,\>1.5\* ULN; lymphocytes (Abs, %), total neutrophils (Abs,%):\<0.8\* LLN, \>1.2\* ULN; Basophils (Abs,%),eosinophils(Abs, %),monocytes(Abs, %):\>1.2\* ULN; total bilirubin,direct bilirubin,indirect bilirubin:\>1.5\* ULN; AST,ALT,gamma GT, LDH,ALP: \>3.0\* ULN; total protein,albumin: \<0.8\* LLN,\>1.2\* ULN: BUN,creatinine: \>1.3\* ULN;uric acid:\>1.2\* ULN; cholesterol,triglycerides: \>1.3\* ULN; cholesterol (HDL: \<0.8\* LLN; LDL: \>1.2\* ULN); sodium: \<0.95\* LLN, \>1.05\* ULN; potassium, chloride, calcium, bicarbonate: \<0.9\* LLN, \>1.1\* ULN; glucose: \<0.6\* LLN; creatine kinase \>2.0\* ULN; urine specific gravity: \<1.003; urine pH: \<4.5; urine (glucose,protein,blood,nitrite,leukocyte,esterase): \>=1; Urine (RBC,WBC): \>=20; urine epithelial cells:\>=6; urine (casts,granular casts,hyaline casts): \>1; urine bacteria:\>20.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 162 | 670 |
Vital sign abnormalities included greater than or equal to (\>=) 30 millimeter of mercury \[mmHg\] increase in systolic blood pressure (BP), \>=30 mmHg decrease in systolic BP, Systolic BP (less than \[\<\] 90 mmHg), \>=20 mmHg increase in diastolic BP, \>=20 mmHg decrease in diastolic BP, diastolic BP (\<50 mmHg), pulse rate (\<40 beats per minute \[BPM\]), pulse rate (greater than \[\>\] 120 BPM).
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Systolic BP (>=30 mmHg increase) | 20 | 113 |
| Systolic BP (>=30 mmHg decrease) | 19 | 44 |
| Systolic BP (<90 mmHg) | 3 | 13 |
| Diastolic BP (>=20 mmHg increase) | 21 | 137 |
| Diastolic BP (>=20 mmHg decrease) | 37 | 78 |
| Diastolic BP (<50 mmHg) | 3 | 16 |
| Pulse Rate (<40 BPM) | 1 | 0 |
| Pulse Rate (>120 BPM) | 0 | 8 |
Physical examinations included weight, general appearance, head, ears, eyes, nose, mouth, throat, thyroid, skin (presence of rash), lungs (auscultation), heart (auscultation for presence of murmurs, gallops, rubs, peripheral edema), abdominal (palpation and auscultation), perianal, musculoskeletal, extremities, neurologic (mental status, gait, reflexes, motor and sensory function, coordination) and lymph nodes. Clinically significant changes were judged by the investigator.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examinations From Baseline | 84 | 391 |
ECG abnormalities criteria: maximum PR interval (\>=300 millisecond); maximum QRS complex (\>=200 millisecond); and maximum QT interval (\>=500 millisecond).
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Maximum PR interval (>=300) | 0 | 0 |
| Maximum QRS complex (>=200) | 0 | 0 |
| Maximum QT interval (>=500) | 0 | 0 |
Incidence rates for adjudicated cardiovascular (major adverse cardiovascular event \[MACE\]), malignancy (non-melanoma skin cancer \[NMSC\], malignancies excluding NMSC, opportunistic infections (OIs) (both herpes zoster and non herpes zoster OIs) and thromboembolic (venous thromboembolism) safety events were analyzed. This outcome measure was measured in participants with events per 100 participants-years (pt with events/100 pts-yrs).
| pt with events/100 pts-yrs | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Major adverse cardiovascular event (MACE) | 0.31 (0.04 to 1.13) | 0.11 (0.01 to 0.40) |
| Nonmelanoma skin cancer (NMSC) | 0.96 (0.35 to 2.08) | 0.68 (0.35 to 1.19) |
| Malignancies excluding NMSC | 1.09 (0.44 to 2.25) | 1.00 (0.60 to 1.59) |
| Herpes Zoster OI | 0.47 (0.10 to 1.37) | 0.79 (0.43 to 1.32) |
| Non Herpes Zoster OIs | 0.16 (0.00 to 0.87) | 0.17 (0.03 to 0.49) |
| Venous thromboembolism | 0.00 (0.00 to 0.57) | 0.33 (0.12 to 0.73) |
Remission in participants was defined as a total Mayo score of less than or equals to (\<=) 2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of ulcerative colitis (UC). It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and physician global assessment (PGA), each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 2 | 131 | 188 |
| Month 12 | 129 | 279 |
| Month 24 | 103 | 264 |
| Month 36 | 98 | 239 |
Remission in participants was defined as a total Mayo score of \<=2, with no individual sub score exceeding 1 point and a rectal bleeding sub score of 0. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 2 | 131 | 188 |
| Month 12 | 129 | 279 |
| Month 24 | 103 | 264 |
| Month 36 | 103 | 259 |
Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 2 | 132 | 191 |
| Month 12 | 129 | 282 |
| Month 24 | 104 | 266 |
| Month 36 | 102 | 240 |
Clinical remission in participants was defined as a total Mayo score of \<=2 with no individual sub score exceeding 1 point. Mayo score was an instrument designed to measure disease activity of UC. It consisted of 4 sub scores: stool frequency, rectal bleeding, findings of flexible sigmoidoscopy and PGA, each graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total Mayo score range of 0 to 12, where higher score indicated more severe disease.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 2 | 132 | 191 |
| Month 12 | 129 | 282 |
| Month 24 | 104 | 266 |
| Month 36 | 107 | 260 |
PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 1 | 158 | 275 |
| Month 4 | 152 | 375 |
| Month 6 | 155 | 395 |
| Month 9 | 154 | 390 |
| Month 15 | 139 | 361 |
| Month 18 | 137 | 354 |
| Month 21 | 125 | 351 |
| Month 27 | 117 | 319 |
| Month 30 | 117 | 307 |
| Month 33 | 111 | 304 |
| Month 39 | 102 | 261 |
| Month 42 | 95 | 236 |
| Month 45 | 95 | 212 |
| Month 48 | 87 | 183 |
| Month 51 | 87 | 162 |
| Month 54 | 68 | 140 |
| Month 57 | 54 | 120 |
| Month 60 | 38 | 98 |
| Month 63 | 28 | 80 |
| Month 66 | 19 | 67 |
| Month 69 | 10 | 49 |
| Month 72 | 6 | 40 |
| Month 75 | 3 | 24 |
| Month 78 | 4 | 18 |
| Month 81 | — | 10 |
| Month 84 | — | 6 |
PMS was an instrument designed to measure disease activity of UC without endoscopy. It consisted of 3 sub scores: stool frequency, rectal bleeding and PGA, each sub score graded from 0 to 3 with higher scores indicated higher disease severity. These sub scores were summed up to give a total PMS score range of 0 to 9, where higher score indicated more severe disease. PMS remission was defined as a partial Mayo score \<=2 with no individual sub score \>1.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 1 | 158 | 275 |
| Month 4 | 152 | 375 |
| Month 6 | 155 | 395 |
| Month 9 | 154 | 390 |
| Month 15 | 139 | 361 |
| Month 18 | 137 | 354 |
| Month 21 | 125 | 351 |
| Month 27 | 117 | 325 |
| Month 30 | 117 | 316 |
| Month 33 | 114 | 317 |
| Month 39 | 108 | 293 |
| Month 42 | 102 | 286 |
| Month 45 | 102 | 283 |
| Month 48 | 95 | 274 |
| Month 51 | 96 | 267 |
| Month 54 | 76 | 250 |
| Month 57 | 61 | 234 |
| Month 60 | 44 | 213 |
| Month 63 | 31 | 194 |
| Month 66 | 22 | 168 |
| Month 69 | 13 | 131 |
| Month 72 | 7 | 102 |
| Month 75 | 3 | 73 |
| Month 78 | 4 | 52 |
| Month 81 | 0 | 29 |
| Month 84 | 0 | 15 |
Mucosal healing in participants was defined as Mayo endoscopic sub score of 0 or 1. The Mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicated higher disease severity.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 2 | 152 | 279 |
| Month 12 | 140 | 340 |
| Month 24 | 119 | 307 |
| Month 36 | 107 | 265 |
Mucosal healing in participants was defined as mayo endoscopic sub score of 0 or 1. The mayo endoscopic sub score consisted of the findings of flexible sigmoidoscopy, graded from 0 to 3 with higher sub scores indicating higher disease severity.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 2 | 152 | 279 |
| Month 12 | 140 | 340 |
| Month 24 | 119 | 307 |
| Month 36 | 113 | 285 |
IBDQ was a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease-specific quality of life in participants with inflammatory bowel disease (IBD), including ulcerative colitis consisted of 32 items scored from 1 (worst response) to 7 (best response). For each domain, higher score indicates better quality of life (QOL). Total IBDQ score was the sum of each item score, and ranged from 32 to 224 with a higher score indicated better QOL.
| Participants | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Month 2 | 154 | 419 |
| Month 6 | 151 | 395 |
| Month 12 | 140 | 365 |
| Month 18 | 123 | 354 |
| Month 24 | 120 | 315 |
| Month 30 | 115 | 299 |
| Month 36 | 111 | 294 |
| Month 48 | 93 | 265 |
| Month 60 | 45 | 215 |
| Month 72 | 8 | 99 |
| Month 84 | 0 | 14 |
Collected over Baseline up to 28 days after last dose of study drug (up to 81 months for Tofacitinib 5 mg BID group and up to 85 months for Tofacitinib 10 mg BID group). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 5 mg BID | 0/175 (0%) | 39/175 (22.3%) | 134/175 (76.6%) |
| Tofacitinib 10 mg BID | 6/769 (0.8%) | 147/769 (19.1%) | 550/769 (71.5%) |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 4/175 | 38/769 |
| Foot fractureInjury, poisoning and procedural complications | 2/175 | 0/769 |
| Ligament ruptureInjury, poisoning and procedural complications | 2/175 | 0/769 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/175 | 2/769 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/175 | 0/769 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/175 | 5/769 |
| Acute myocardial infarctionCardiac disorders | 1/175 | 0/769 |
| Angina pectorisCardiac disorders | 1/175 | 2/769 |
| Atrial fibrillationCardiac disorders | 1/175 | 0/769 |
| Cardiac failureCardiac disorders | 1/175 | 0/769 |
| Event | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID |
|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 44/175 | 131/769 |
| NasopharyngitisInfections and infestations | 41/175 | 157/769 |
| InfluenzaInfections and infestations | 23/175 | 63/769 |
| Blood creatine phosphokinase increasedInvestigations | 19/175 | 85/769 |
| Upper respiratory tract infectionInfections and infestations | 19/175 | 77/769 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 17/175 | 76/769 |
| BronchitisInfections and infestations | 17/175 | 30/769 |
| HypertensionVascular disorders | 17/175 | 28/769 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/175 | 38/769 |
| Urinary tract infectionInfections and infestations | 13/175 | 34/769 |
Full analysis set (FAS) included all participants who received at least 1 dose of study medication in this study.
| Age, Continuous(years) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
|---|---|---|---|
| Mean | 44.5 ± 14.6 | 40.5 ± 13.5 | 41.2 ± 13.8 |
| Sex: Female, Male(Participants) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
|---|---|---|---|
| Female | 79 | 310 | 389 |
| Male | 96 | 459 | 555 |
| Race/Ethnicity, Customized(Participants) | Tofacitinib 5 mg BID | Tofacitinib 10 mg BID | Total |
|---|---|---|---|
| White | 136 | 615 | 751 |
| Black | 0 | 9 | 9 |
| Asian | 25 | 97 | 122 |
| Other | 9 | 24 | 33 |
| Unspecified | 5 | 24 | 29 |
Showing the first 100 of 252 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2012 to primary completion in Aug 2020, 94 months.
Results were first posted in Sep 2021, 1 year 1 month after primary completion.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 94 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib